Solvista Healthcare Pvt. Ltd. is a PCD Pharma Franchise company that offers business opportunities for a pharmaceutical distributorship on a PCD basis throughout India. The company lays emphasis on high-quality healthcare products and helps its franchise partners with territory-exclusive business opportunities, marketing strategies, and sales promotion material for products.
Solvista Healthcare is WHO-GMP certified for its manufacturing plants and also has stringent quality control measures for pharmaceutical medicines. Its product segment encompasses a range of pharmaceuticals that include tablets, capsules, syrups, sachets, ointments, paediatric medicines, ayurvedic formulations, cardiac medicines, and various others. In addition, its range covers general medicine, cardiology, dermatology, paediatric, and nutraceutical therapeutic areas. For the PCD franchise, the company offers monopoly rights in exclusive territories to its partners along with effective marketing support such as aids, visual aids, product literature, samples and MR bags.
| Basic Information | |
|---|---|
| Company Name | Solvista Healthcare Pvt. Ltd. |
| Nature of Business | PCD Pharma Franchise |
| Business Type | Pharmaceutical Company |
| Franchise Model | Monopoly-Based PCD Pharma Franchise |
| Market Presence | PAN India |
| Manufacturing Standard | WHO-GMP Certified Facilities |
| Product Portfolio | 300+ Products |
| Major Product Categories | Tablets, Capsules, Syrups, Sachets, Ointments, Paediatric & Ayurvedic Products |
| Therapeutic Segments | General Medicine, Cardiology, Dermatology, Pediatrics & Nutraceuticals |
| Franchise Support | Monopoly Rights, Marketing & Promotional Support |
| Promotional Materials | Visual Aids, Product Literature, Samples, MR Bags & Other Marketing Materials |
| Quality Focus | Quality Control Testing, Stability Checks & Batch Verification |
| Business Opportunity | Pharmaceutical Franchise & Distribution |
| Target Partners | Pharma Professionals, Distributors, Medical Representatives & Entrepreneurs |
Leave a Reply